SuperworthC4 Therapeutics price to book ratio CCCC
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 1.5×
- 6-year median
- 1.3×
- Against its 6-year history
- 61st
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.3× to 7.1×
- Peer median
- 5.0×
C4 Therapeutics' price to book ratio is 1.5× as of Oct 23, 2026.
That is above its 6-year median of 1.3×, close to the middle of its last 6 years.
Over that time it ranged from 0.3× in Oct 2023 to 7.1× in Jul 2021.
The median for 4 biotech stocks of a similar size is 5.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.5× | 0.9× | 2.1× |
| 2025 | 1.3× | 0.4× | 1.7× |
| 2024 | 1.1× | 1.1× | 3.1× |
| 2023 | 1.3× | 0.3× | 1.3× |
| 2022 | 0.9× | 0.7× | 3.4× |
| 2021 | 3.9× | 3.8× | 7.1× |
Against its peers
Companies in Biotechnology nearest C4 Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CCCCC4 Therapeutics | 1.5× |
| PLXProtalix BioTherapeutics | 2.9× |
| MGTXMeiraGTx | 4.1× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| Peer median | 5.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on C4 Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.